OTCMKTS:CEOS Psykey (CEOS) Stock Price, News & Analysis $0.0061 0.00 (-25.61%) As of 02:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Psykey Stock (OTCMKTS:CEOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Psykey alerts:Sign Up Key Stats Today's Range$0.0051▼$0.009250-Day Range$0.0056▼$0.012052-Week Range$0.00▼$0.04Volume110,534 shsAverage Volume438,614 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada. Read More Receive CEOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psykey and its competitors with MarketBeat's FREE daily newsletter. Email Address CEOS Stock News HeadlinesCeCors, Inc.: CEOS Engages National Law Firm as Outside Counsel, Prepares for Further GrowthJanuary 7, 2025 | finanznachrichten.deCEOS Engages National Law Firm as Outside Counsel, Prepares for Further GrowthJanuary 7, 2025 | finance.yahoo.comCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 22 at 2:00 AM | Investors Alley (Ad)CeCors, Inc.: CeCors Announces Leadership Transition - Michael Maher, Distinguished Veteran and Leader, Named Interim CEOJanuary 1, 2025 | finanznachrichten.deAmerica’s CEOs don’t have the stomach for Trump’s promised revenge tourOctober 31, 2024 | cnn.comFortune 500 CEOs Have Made Their Choice Between Trump and Biden, Reveals Top Business School Prof.October 22, 2024 | msn.comPsykey, Inc. (CEOS) Stock Price, News, Quote & History - Yahoo FinanceOctober 19, 2024 | finance.yahoo.comMeet the Silicon Valley billionaires, corporate CEOS, and founders backing Kamala HarrisOctober 10, 2024 | businessinsider.comSee More Headlines CEOS Stock Analysis - Frequently Asked Questions How have CEOS shares performed this year? Psykey's stock was trading at $0.0390 at the beginning of the year. Since then, CEOS stock has decreased by 84.4% and is now trading at $0.0061. How do I buy shares of Psykey? Shares of CEOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Psykey own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psykey investors own include Fernhill (FERN), Iconic Minerals (ICM), Puget Technologies (PUGE), Tonix Pharmaceuticals (TNXP), Amazonas Florestal (AZFL), Ayr Strategies (AYRSF) and Anavex Life Sciences (AVXL). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Instruments & Supplies Sub-IndustryWholesale Current SymbolOTCMKTS:CEOS CIKN/A Webwww.cecorsinc.com Phone(877) 348-1155FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:CEOS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psykey, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psykey With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.